Published in J Clin Oncol on December 10, 2006
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol (2009) 1.40
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol (2008) 1.25
Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res (2012) 1.25
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol (2011) 1.20
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem (2011) 1.14
Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res (2009) 1.13
Integrative modelling of the influence of MAPK network on cancer cell fate decision. PLoS Comput Biol (2013) 1.09
Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget (2014) 1.05
Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis (2010) 1.00
Molecular screening for bladder cancer: progress and potential. Nat Rev Urol (2010) 0.97
Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res (2014) 0.95
Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93
Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol (2013) 0.93
Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer (2008) 0.89
Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol (2012) 0.88
Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther (2010) 0.88
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell Int (2013) 0.85
Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol (2010) 0.84
p53 and chemosensitivity in bladder cancer. Int J Clin Oncol (2008) 0.84
Epigenetics in bladder cancer. Int J Clin Oncol (2008) 0.84
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One (2014) 0.83
Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget (2014) 0.83
Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol (2016) 0.82
Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev (2012) 0.82
Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer. Oncol Lett (2014) 0.82
Alterations of gene expression of RB pathway in Opisthorchis viverrini infection-induced cholangiocarcinoma. Parasitol Res (2009) 0.80
Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J Urol (2011) 0.80
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
[Update on urothelial carcinoma histopathology]. Pathologe (2008) 0.79
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res (2016) 0.79
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site. PLoS One (2013) 0.78
Significant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma. Acta Histochem Cytochem (2012) 0.78
Molecular targets and targeted therapies in bladder cancer management. World J Urol (2008) 0.78
N‑Myc downstream‑regulated gene 2 suppresses the proliferation of T24 human bladder cancer cells via induction of oncosis. Mol Med Rep (2015) 0.77
Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. Biomed Res Int (2015) 0.77
Ginsenoside Rg3 Inhibits Constitutive Activation of NF-κB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets. J Cancer Prev (2014) 0.77
Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma. World J Urol (2013) 0.77
Identification of molecular targets in urologic oncology. World J Urol (2008) 0.77
Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. Int J Clin Exp Pathol (2015) 0.76
Advances in gas chromatographic methods for the identification of biomarkers in cancer. J Cancer (2012) 0.76
Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther (2012) 0.76
Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.76
Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis. Indian J Urol (2008) 0.75
Pathway Analysis Based on Attractor and Cross Talk in Colon Cancer. Dis Markers (2016) 0.75
Identification of a Novel UT-B Urea Transporter in Human Urothelial Cancer. Front Physiol (2017) 0.75
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. Drug Des Devel Ther (2016) 0.75
Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion. Eur J Pharmacol (2015) 0.75
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention. Oncol Rev (2016) 0.75
Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins. Br J Cancer (2015) 0.75
UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study. Contemp Oncol (Pozn) (2013) 0.75
Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure. Oncotarget (2017) 0.75
Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4(th) Edition Guidelines as a Molecular Insight towards Personalized Medicine. Open Access Maced J Med Sci (2017) 0.75
Current topics and perspectives in bladder cancer research. Int J Clin Oncol (2008) 0.75
1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget (2017) 0.75
[Urothelial carcinoma. Does surgical pathology learn from molecular pathology?]. Pathologe (2008) 0.75
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A (2007) 3.48
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem (2002) 2.16
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices (2011) 2.10
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. J Am Chem Soc (2005) 1.97
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol (2009) 1.79
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol (2004) 1.77
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol (2007) 1.74
Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res (2006) 1.73
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer (2006) 1.44
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer (2008) 1.39
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
Circulating tumor cells: from bench to bedside. Annu Rev Med (2012) 1.29
Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. Am J Clin Pathol (2008) 1.21
High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn (2009) 1.21
Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol (2010) 1.20
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol (2010) 1.15
Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes. ACS Nano (2009) 1.14
Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther (2007) 1.13
Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Molecular staging of bladder cancer. BJU Int (2005) 1.02
Molecular screening for bladder cancer: progress and potential. Nat Rev Urol (2010) 0.97
A calibration method for nanowire biosensors to suppress device-to-device variation. ACS Nano (2009) 0.97
Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev (2009) 0.97
Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer (2006) 0.96
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int (2009) 0.94
LM-PCR permits highly representative whole genome amplification of DNA isolated from small number of cells and paraffin-embedded tumor tissue sections. Diagn Mol Pathol (2004) 0.94
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn (2012) 0.92
Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int (2006) 0.92
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer (2004) 0.89
Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol (2012) 0.88
Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther (2010) 0.88
Genetic and epigenetic analysis of putative breast cancer stem cell models. BMC Cancer (2013) 0.87
Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. Prostate (2008) 0.87
Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res (2005) 0.85
Rapid, label-free, electrical whole blood bioassay based on nanobiosensor systems. ACS Nano (2011) 0.85
Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India (2006) 0.84
A modified reduced-temperature antigen retrieval protocol effective for use with a polyclonal antibody to cyclooxygenase-2 (PG 27). Appl Immunohistochem Mol Morphol (2002) 0.83
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol (2012) 0.81
The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol (2004) 0.80
Role of genetic and expression profiling in pharmacogenomics: the changing face of patient management. Curr Issues Mol Biol (2002) 0.79
Medical applications of nanotechnology. Natl Med J India (2006) 0.79
Micrometastasis: detection methods and clinical importance. Cancer Biomark (2010) 0.79
Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol (2005) 0.79
Searching for novel therapeutics and targets: insights from clinical trials. Urol Oncol (2007) 0.78
Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol (2003) 0.78
Molecular targets and targeted therapies in bladder cancer management. World J Urol (2008) 0.78
The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. Urol Oncol (2007) 0.77
Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin Chem (2011) 0.77
Classical pathology versus molecular pathology in renal cell carcinoma. Curr Urol Rep (2007) 0.77
Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales? Expert Rev Anticancer Ther (2011) 0.77
Importance of controlling nanotube density for highly sensitive and reliable biosensors functional in physiological conditions. ACS Nano (2010) 0.77
Prevention of prostate cancer with finasteride. N Engl J Med (2003) 0.77
Pathological possibilities and pitfalls in detecting aggressive bladder cancer. Curr Opin Urol (2012) 0.76